Merck KGaA Buys Into Threshold Cancer Drug | Chemical & Engineering News
Volume 90 Issue 7 | p. 21 | Concentrates
Issue Date: February 13, 2012

Merck KGaA Buys Into Threshold Cancer Drug

Department: Business
Keywords: pharmaceuticals, hypoxia, pancreatic cancer

Merck KGaA will pay Threshold Pharmaceuticals $25 million up front and up to $525 million in milestones for access to the cancer treatment TH-302. Merck will also cover 70% of the development costs for TH-302, a small molecule that is activated in tumor cell environments where the oxygen concentration is low. A Phase III trial testing the compound in soft-tissue sarcoma is under way, and Threshold expects to reveal data from a Phase II trial in pancreatic cancer later this month. Threshold retains an option to jointly sell the drug in the U.S.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment